High intraday volume GV.PA Genomic Vision SA EURONEXT €0.002 02 Feb 2026: watch

We see GV.PA stock trading at €0.002 on EURONEXT during intraday trade on 02 Feb 2026, with 38,489,238 shares changing hands. This spike lifts the share price about +5.88% on the day and sends a clear signal that short-term traders are active. The micro-cap healthcare name shows a market cap of about €693,191 and an EPS of -0.11, underlining high volatility and limited liquidity for intraday moves.

Intraday price action and volume for GV.PA stock

GV.PA stock opened at €0.002 and printed a day low of €0.0015 and a day high of €0.002. Volume at 38,489,238 is 2.71 times the average volume of 14,217,513, which makes today one of the most active intraday sessions for the ticker. High relative volume on a micro-cap like Genomic Vision SA often reflects short-term speculation or a tradeable scalp for liquidity-seeking traders.

Company profile, sector context and key drivers

Genomic Vision SA (GV.PA) is a France-based diagnostics and molecular tools company listed on EURONEXT in Europe. The company sells FiberVision and related molecular combing tools and has strategic alliances with Quest Diagnostics and Institut Pasteur. Healthcare sector performance is soft YTD at -1.90%, which places GV.PA in a cautious sector background despite today’s volume spike.

Valuation and financial metrics for GV.PA stock

The stock trades well below its 50-day average of €0.005 and 200-day average of €0.014, signalling a long downtrend. Reported EPS is -0.11 and the trailing PE is negative. Price-to-sales is 0.47, enterprise value to sales is 1.60, and current ratio is 0.91, showing constrained liquidity. Market cap is about €693,191 with 385,105,984 shares outstanding.

Technicals, liquidity and trading risks for GV.PA stock

Liquidity is the primary trading risk: low nominal price with concentrated shares creates wide bid-ask spreads and fast moves. Average daily volume is 14,217,513, but today’s volume surge increases short-term liquidity. Technicals show the price below key moving averages; a sustained move above €0.005 (50-day) would change momentum, but failure to hold €0.0015 risks new intraday weakness.

Meyka AI rates GV.PA with a score out of 100

Meyka AI rates GV.PA with a score out of 100: 58.59 | Grade: C+ | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade emphasises weak fundamentals, constrained liquidity, and mixed sector context, and is informational only and not financial advice.

Catalysts, opportunities and downside scenarios for GV.PA stock

Near-term catalysts include contract wins, stronger combing service demand, or renewed partner activity with Quest Diagnostics or hospitals. Upside events must overcome tight liquidity and negative earnings. Downside scenarios include dilution, weak cash flow, or loss of partnerships given the negative operating cash flow per share and thin cash buffer. Traders should size positions conservatively.

Final Thoughts

Key takeaways for GV.PA stock: intraday trade on 02 Feb 2026 shows €0.002 with heavy 38,489,238 volume, signalling active short-term interest on EURONEXT in Europe. Fundamentals remain weak with EPS -0.11, negative operating cash flow per share, and a market cap of €693,191. Meyka AI’s forecast model projects €0.005 in 12 months compared with the current price €0.0018, implying a theoretical upside of 177.78%, but forecasts are model-based projections and not guarantees. Given limited liquidity, negative margins, and sector headwinds, we frame GV.PA as a high-risk, speculative holding best suited to traders, not core investors. We note that macro moves can amplify intraday swings; stay size-conscious and monitor news and partner developments.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.